Skip to content
#protein folding Open access

Mechanisms of Lipid Metabolism Disorders in Experimental Non-Alcoholic Fatty Liver Disease: The Role of LDLR, LOX-1, ApoE and LRP1

Aug 2026 · International journal of medical science and dental health · 0 citations
Liver Disease Diagnosis and Treatment

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disorder and is closely linked to insulin resistance and the metabolic syndrome. Beyond the accumulation of triacylglycerides (TAG), disturbed hepatic cholesterol handling — mediated by the low-density lipoprotein receptor (LDLR), the lectin-like oxidised LDL receptor-1 (LOX-1), apolipoprotein E (ApoE) and LDL receptor-related protein 1 (LRP1) — has been proposed as a central pathogenetic mechanism. Objective: To evaluate the serum protein factors involved in triacylglyceride and cholesterol metabolism during the stepwise development of experimental fatty hepatosis. Methods: Fifty outbred white rats weighing 150–180 g were studied. Eight animals formed the intact group and received a standard vivarium diet; 42 animals received a high-fat diet (cow lard) supplemented with a 10% glucose–fructose solution (1:1) for 5 months. Serum was examined at 2, 3, 4 and 5 months. Total protein, albumin, bilirubin, urea, glucose, TAG, total cholesterol (TC) and cholesterol in very-low-density (VLDL-C), low-density (LDL-C) and high-density (HDL-C) lipoproteins were measured, and the atherogenic index (AI) together with ALT, AST, GGT and ALP activities were determined. Insulin, LDLR, LOX-1, ApoE and LRP1 were measured by sandwich enzyme-linked immunosorbent assay. HOMA-IR, the TAG/HDL-C ratio and the metabolic index (MI) were calculated. Results: High-calorie feeding produced a progressive increase in serum TAG (up to 2.11-fold) and TC (up to 1.93-fold), a rise in VLDL-C (up to 2.96-fold) and LDL-C (up to 4.19-fold) and a fall in HDL-C, with the AI increasing from 0.66 ± 0.03 to 3.66 ± 0.28 (5.54-fold; P < 0.001). Glucose rose 1.49-fold, insulin 2.73-fold and HOMA-IR 3.13-fold by month 5. Serum LDLR fell progressively (2.41-, 3.34- and 4.89-fold at 2, 3 and 4 months, with partial recovery to a 3.61-fold reduction at 5 months), whereas LOX-1 rose (1.63-, 2.03-, 2.18- and 1.94-fold). ApoE showed a biphasic pattern: a 1.52-fold decrease at 2 months followed by a rise above intact values at 4 (1.32-fold) and 5 months (1.23-fold). LRP1 was unchanged at 2 months and then decreased by 1.25-, 1.40- and 1.43-fold. Conclusion: Prolonged high-calorie feeding reproduces fatty hepatosis accompanied by the full biochemical picture of the metabolic syndrome. The progressive decline of LDLR together with a rise in LOX-1, a biphasic ApoE response and a gradual reduction of LRP1 indicate a dysregulation of receptor-mediated hepatic cholesterol handling and suggest that these proteins merit further evaluation as early markers of fatty hepatosis.

Read PDF

Similar papers

Open access Sep 2026

Cholesterol Metabolism Regulation by Native and Oxidized Low-Density Lipoprotein in a Liver Cell Line.

AIMS Metabolic dysfunction-associated steatohepatitis (MASLD) is a highly prevalent chronic liver disease. Oxidized low-density lipoprotein (oxLDL) is implicated in MASLD progression; however, its effects on the hepatic cholesterol metabolism remain unclear. Therefore, we explored the effects of native LDL (nLDL) and o...

Nakyoung Kim, T. Sakurai, Himeno Sakuma et al. · 0 citations
Open access Sep 2026

Influence of ursodeoxycholic acid on hepatic lipid deposition, blood glucose, and insulin levels in high-fat -fed Sprague–Dawley rats

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming a growing public health concern. MASLD often coexists with abnormal glucose metabolism. Currently, there is no standard treatment for MASLD. Aim: To elucidate the influence of ursodeoxycholic acid (UDCA) on hepatic lipid deposition...

Xiu-Ping Bai, Yu-Feng Han, Ling-Yan Wei et al. · 0 citations
Review Open access Sep 2026

The role of thyroid hormone beta 1 receptor (THRβ1) in metabolic dysfunction associated steatohepatitis (MASH): from dysregulation to therapeutic target.

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is still one of the most common chronic liver diseases worldwide. The build-up of triglycerides in the liver is a key feature of MASLD and can lead to oxidative stress and inflammation, there...

R. Patil, G. Viswanatha, Sai Balaji Andugulapati et al. · 0 citations
Review Open access Sep 2026

Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the “Liver–Other Organs” Axes

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease and is closely associated with obesity, insulin resistance, and the recently conceptualized cardiovascular–kidney–metabolic syndrome. For decades, the pathogenesis of steatosis has been viewed primarily through the...

S. Kotlyarov, A. Kotlyarova, R. Catanzaro et al. · 0 citations
Open access Sep 2026

Progressive Metabolic Changes During High-Cholesterol Diet Feeding and Attenuation by PNBio in a Rabbit Model of MASLD

Background: prolonged dietary cholesterol exposure can progressively disrupt lipid and glucose metabolism and promote hepatic lipid accumulation; metabolic features associated with metabolic dysfunction-associated steatotic liver disease (MASLD). The present study evaluated the preventive effect of a polyherbal nutrace...

Akhlaq A. Mehras, Maya G. Pillai, Salu V. S. et al. · 0 citations

Related blog posts

Google DeepMind Blog Sep 30, 2026

Introducing SynthID Bio

Proof of concept for watermarking AI-generated proteins while preserving biological function.

MIT News · Artificial Intelligence Aug 27, 2026

Looking beyond natural sequences

A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.